East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians

Wei Zhou¹ and David C. Christiani²,³

Abstract

Lung cancer is the leading cause of cancer death worldwide, with large variation of the incidence and mortality across regions. Although the mortality of lung cancer has been decreasing, or steady in the US, it has been increasing in Asia for the past two decades. Smoking is the leading cause of lung cancer, and other risk factors such as indoor coal burning, cooking fumes, and infections may play important roles in the development of lung cancer among Asian never-smoking women. The median age of diagnosis in Asian patients with lung cancer is generally younger than Caucasian patients, particularly among never-smokers. Asians and Caucasians may have different genetic susceptibilities to lung cancer, as evidenced from candidate polymorphisms and genome-wide association studies. Recent epidemiologic studies and clinical trials have shown consistently that Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC), independent of smoking status. Compared with Caucasian patients with NSCLC, East Asian patients have a much higher prevalence of epidermal growth factor receptor (EGFR) mutation (approximately 30% vs. 7%, predominantly among patients with adenocarcinoma and never-smokers), a lower prevalence of K-Ras mutation (less than 10% vs. 18%, predominantly among patients with adenocarcinoma and smokers), and higher proportion of patients who are responsive to EGFR tyrosine kinase inhibitors. The ethnic differences in epidemiology and clinical behaviors should be taken into account when conducting global clinical trials that include different ethnic populations.

Key words Lung cancer, ethnicity, Asian, EGFR, K-Ras

Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death worldwide. Lung cancer accounted for 13% (1.6 million) of the total cancer cases and 18% (1.4 million) of the cancer deaths in 2008[1]. There is a large variation of the incidence and mortality rate of lung cancer in the world. In males, the highest lung cancer incidence rates are in Central/Eastern and Southern Europe (age-standardized rate, ASR, of 57 and 49 per 100,000, respectively), North America (ASR of 48.5 per 100,000), and Eastern Asia (ASR of 45 per 100,000). In females, the highest lung cancer incidence rates are found in North America (ASR of 35.8 per 100,000), Northern Europe (ASR of 21.8 per 100,000), and Eastern Asia (ASR of 19.9 per 100,000)[1]. The different incidence between men and women explains that in the US, approximately 45% of patients with NSCLC are women. However, in Eastern Asia, only 25% to 30% of patients with lung cancer are women[2,3].

Epidemiology, Environment, and Genetic Susceptibility of Lung Cancer Patients in Asia and the US

There are other differences in characteristics of lung cancer patients between Asia and the US. Compared with patients in the US, Asian patients have generally a younger age of onset. In addition, the median age of Asian never-smoker patients (defined as never smoked or smoked less than 100 cigarettes in the lifetime) is significantly younger than ever-smoker patients; whereas in the US, the median age of never-smoker patients is...
Chin study concluded that common genetic variants in the significance with 6p21.33, and 15q25 that have achieved genome-wide identified three regions on chromosomes 5p15.33, 6p21.33, and 15q25 for lung cancer overall or for the adenocarcinoma subtype[12]. It is not clear whether the differences are due to different smoking status, or ethnicity, or some other variable(s).

Survival and Prognostic Differences Between Lung Cancer Patients in Asia and the US

Several large epidemiologic studies suggested that Asian ethnicity is a favorable prognostic factor for overall survival (OS) of patients with non–small cell lung cancer (NSCLC, which accounts for ~85% of all lung cancers) and is independent of smoking status[2,3,13]. A recent retrospective population-based analysis of 15,185 Japanese and 13,332 US Caucasian NSCLC patients treated between 1991 and 2001 suggested that Japanese ethnicity [vs. Caucasian: hazard ratio (HR) = 0.937, 95% confidence interval (CI) = 0.909–0.987, P = 0.003] and never-smoker status [vs. ever-smoker: HR = 0.947, 95% CI = 0.909–0.987, P = 0.010] are independent favorable factors for OS in addition to younger age, female gender, early stage, and treatment received[8]. The results were confirmed by a retrospective population-based analysis of 4,622 Korean and 8,846 US Caucasian NSCLC patients, with an adjusted hazard ratio of 0.869 (P < 0.0001) for Korean vs. Caucasian patients[5]. Another retrospective population-based study of 20,140 NSCLC patients from the cancer surveillance programs of three Southern California counties suggested that even within the US, Asian ethnicity is an independent and favorable prognostic factor for OS [vs. non-Asian: HR = 0.861, 95% CI = 0.808–0.918], among both smokers (vs. non-Asian: HR = 0.867, 95% CI = 0.807–0.931) and never-smokers (vs. non-Asian: HR = 0.841, 95% CI = 0.728–0.971), adjusting for covariates such as age, gender, smoking status, pathology, and treatment[13]. Similar results were observed after stratification by stage. It is not clear whether these Asian American NSCLC patients were born in their native countries, and whether this ethnic difference will hold after the first generation. In another study with 1,124 Asian American NSCLC patients including 5 major Asian American subgroups (Filipino, Vietnamese, Japanese, Chinese, and Korean), there was no statistically significant difference in clinicopathologic features or survival outcome between individual Asian American subgroups when analyzed according to smoking status,
nor survival difference between never-smokers and ever-smokers (11 vs. 10 months; \( P = 0.30 \) [14]. Except for Japanese American, most of the other ethnicity subgroups were born in their native countries. Analyses on Japanese patients suggested that the proportion of Japanese never-smokers was higher among native Japanese (17.2\%) than non-native Japanese (11.6\%) NSCLC patients [14].

In addition to epidemiologic studies, a recent randomized clinical trial of first-line chemotherapy among advanced epidermal growth factor receptor (EGFR)-expressing NSCLC patients showed that Asian patients have about 10 months longer OS compared with Caucasian patients regardless of treatment received, which is partially explained by different demographics (e.g. younger age of onset, higher proportion of never-smokers) and more frequent use of EGFR tyrosine kinase inhibitors (TKIs) in Asian patients (61\% in Asian vs. 17\% in Caucasian) in subsequent lines of treatment [15]. Another study analyzed results from three phase III trials suggesting a 3- to 5-month OS improvement in Japanese NSCLC patients compared to US patients who received carboplatin/paclitaxel as first-line treatment (12 or 14 months vs. 9 months; \( P = 0.0006 \)). It has been suggested that differences in allelic distribution for clinical trials involved in paclitaxel distribution and deposition (CYP3A4 and CYP3A5) or DNA repair (ERCC1 and ERCC2) may contribute to the different outcome between Japanese and US patients [16].

### Somatic Mutations Among Asian and US Patients with Lung Cancer

Treatment of NSCLC, particularly adenocarcinoma, is in the era of personalized medicine, with the focus on the development of innovative treatment options, particularly new target-based therapies directed against key signaling pathways involved in lung cancer growth and malignant progression. Many biomarkers, including EGFR and K-Ras somatic mutations, ERCC1/RRM1 mRNA expression, and EML-ALK4 translocation, have been tested for patient screening in clinical trials and/or clinical treatment. Among these, EGFR and K-Ras mutations have clearly demonstrated different characteristics between NSCLC patients in Asian and Caucasian populations [17-20].

### EGFR mutation

EGFR, a cell membrane receptor with tyrosine kinase activity, is expressed in most patients with NSCLC and plays an important role in cellular proliferation, inhibition of apoptosis, angiogenesis, metastatic potential, and chemoresistance. EGFR mutation has been proven to be a predictive biomarker for EGFR-TKIs, both for gefitinib and erlotinib, among both Asian and Western NSCLC patients. The IRESSA Pan-Asia Study (IPASS) phase III trial compared first-line carboplatin and paclitaxel with gefitinib in East Asian never-smokers or former light smokers with lung adenocarcinoma [20]. The trial demonstrated the superiority of gefitinib compared with carboplatin and paclitaxel in overall response rate (RR, 43.0\% vs. 32.2\%; odds ratio = 1.59, 95\% CI = 1.25–2.01, \( P < 0.001 \)), progression-free survival (PFS, HR = 0.74, 95\% CI = 0.65–0.85, \( P < 0.001 \)), and quality of life, as well as a lower rate of toxicity in the intent-to-treat patient population. In the subgroup of patients with an EGFR mutation, the PFS was significantly longer in the gefitinib arm than in the carboplatin and paclitaxel arm (HR = 0.48, 95\% CI = 0.36–0.64, \( P < 0.001 \)). In contrast, in patients with wild-type EGFR, the PFS was significantly shorter in the gefitinib arm than in the carboplatin and paclitaxel arm (HR = 2.83, 95\% CI = 2.05–3.98, \( P < 0.001 \)). The final analysis of IPASS study showed that median OS was similar between gefitinib and carboplatin/paclitaxel arms in the overall population (18.8 vs. 17.4 months, HR = 0.90, 95\% CI = 0.79–1.02, \( P = 0.11 \)), in EGFR mutant patients (21.6 vs. 21.9 months, HR = 1.00, 95\% CI = 0.76–1.33), in EGFR wild-type patients (11.2 vs. 12.7 months, HR = 1.18, 95\% CI = 0.86–1.63), and in patients whose EGFR mutation status was unknown (18.9 vs. 17.2 months, HR = 0.82, 95\% CI = 0.70–0.96).

Patients with EGFR mutation had better outcomes (median OS, 22 months) than those with wild-type EGFR (median OS, 11–12 months), regardless of which treatment arm they were in [20].

In another phase III OPTIMAL study presented by Zhou et al. [21] at the 2010 European Society for Medical Oncology (ESMO) conference, which randomized 165 Asian patients with advanced NSCLC to first-line erlotinib or gemcitabine/carboplatin chemotherapy doublet, the primary endpoint of PFS was 13.1 months in the erlotinib arm compared to only 4.6 months (HR of 0.16, \( P < 0.0001 \)) in the chemotherapy doublet arm. The benefit provided by treatment with erlotinib was consistent in all subgroups stratified by age, smoking status, and gender.

In addition to Asian studies, a recent press release in January 2011 announced that in the interim analysis of the phase III EURTAC trial by the Spanish Lung Cancer Group with researchers in France and Italy, erlotinib significantly extended PFS among newly diagnosed NSCLC patients with EGFR-activating mutations when compared with a platinum-based chemotherapy regimen. It is the first phase III study to show a PFS benefit with first-line treatment in a Western population with advanced NSCLC harboring EGFR mutations, with the full data to be presented or published soon. An Online Tumor Registry of five clinical trials from the US and
Europe, in which chemotherapy-naive patients with advanced NSCLC were treated with an EGFR-TKI (gefitinib or erlotinib), 56 (67%) EGFR mutant patients achieved an objective response, with a median PFS of 11.8 months and a median OS of 23.9 months. For the 83 patients with wild-type EGFR and wild-type K-Ras, the RR was 5%, the median PFS was 3.1 months, and the median OS was 11.8 months. Among the 41 patients with wild-type EGFR and mutated K-Ras, RR was 0%, PFS was 3.3 months, and median OS was 13 months. Patients with EGFR exon 19 deletions had a longer PFS (14.6 vs. 9.7 months, \( P = 0.02 \)) and OS (30.8 vs. 14.8 months, \( P < 0.001 \)) than those with the L858R mutation[24].

Several demographic and pathological factors are associated with EGFR mutation prevalence. EGFR mutation is mainly observed among patients with adenocarcinoma, never-smokers, and Eastern Asian ethnicity. Among Asian patients, the overall prevalence of EGFR mutations (i.e. exons 18–22) is approximately 30% overall, 47% among patients with adenocarcinoma, and 56% among never-smokers. Among Caucasians, the average EGFR mutation prevalence is approximately 7% overall, 13% among patients with adenocarcinoma, and 35% among never-smokers[20]. The reason for the high frequency of EGFR mutations in Asian patients is unclear, and it is suggested that the CA simple sequence repeat 1 (CA-SSR1), a highly polymorphic locus containing 14 to 21 CA dinucleotide repeats, and polymorphisms in the EGFR promoter regions may play an important role. Studies have suggested that many Asians have polymorphic types that lead to a decreased intrinsic production of EGFR protein. If a certain critical level of EGFR is required to drive the cell toward a malignant phenotype, another mechanism including activating mutations of EGFR and/or autonomously activating downstream signaling may be required for the development of lung cancer among Asians[18,20].

K-Ras mutation

The Ras proteins belong to the small guanosine triphosphatase (GTPase) superfamily. Each Ras gene has a predilection to specific tumors, with K-Ras predominantly found in colorectal, lung, pancreatic, ovarian, endometrial, gastric, and brain cancers, H-Ras in bladder cancer, and N-Ras in melanoma and leukemia. More than 95% of Ras mutations are in codons 12/13 of exon 2. Ras mutation results in activation of Ras protein, inhibition of GTPase activity, resistance to upstream inhibitors, and resistance to EGFR inhibitors.

The overall K-Ras mutation prevalence in patients with NSCLC is approximately 16% (or 18% among Caucasian populations), based on two recent meta-analyses of 22 studies with 1470 NSCLC patients treated with EGFR-TKIs[17,18]. K-Ras mutation is predominantly observed among Caucasian patients with adenocarcinoma (~26% vs. 16% among patients with NSCLC of other cell types, and very uncommon among patients with squamous cell carcinoma) and ever-smokers (25% vs. 6% among never-smokers)[17,18]. A recent study on 482 patients with lung adenocarcinoma (mainly Caucasians) suggested a 15% of K-Ras mutation prevalence among never-smokers, 22% among former smokers, and 25% among current smokers (\( P = 0.12 \))[25]. In addition, never-smokers were significantly more likely than former or current smokers to have a transition mutation (G to A) rather than the transversion mutations (G to T or G to C) known to be smoking-related (\( P < 0.0001 \))[26]. Among Eastern Asian patients with NSCLC, K-Ras mutation prevalence is generally less than 10% and is very rare among squamous cell carcinoma and never-smoker patients[24]. Asbestos exposure may be associated with K-Ras mutation; however, data are limited.

There are inconclusive results on whether K-Ras mutation is a prognostic or predictive factor of advanced NSCLC treated with chemotherapy[27]. K-Ras mutant patients with NSCLC do not generally respond to EGFR-TKIs, and the predictive power of K-Ras mutations for EGFR-TKIs sensitivity was higher in Asians than in Caucasians[19]. However, due to a mutually exclusive relationship between K-Ras and EGFR mutation, and no survival difference between mutant and wild-type K-Ras among EGFR wild-type patients with NSCLC[24], the clinical usefulness of K-Ras mutation as a predictor of EGFR-TKIs sensitivity in patients with NSCLC is limited[19].

EML4-ALK translocation

A recent breakthrough in NSCLC treatment is the discovery of the EML4-ALK fusion-type tyrosine kinase in patients with NSCLC (mostly adenocarcinoma) and the dramatic response of EML4-ALK patients to crizotinib in clinical trials[28,29]. Replacement of the extracellular and trans-membrane domain of ALK with a region of EML4 results in constitutive dimerization of the kinase domain and thereby a consequent increase in its catalytic activity[28]. In a phase I study with 82 advanced NSCLC patients who have mostly failed multiple lines of therapy, the overall response rate of EML4-ALK patients to crizotinib was 57% (46 confirmed partial responses and 1 confirmed complete response), and 27 patients (33%) had stable disease; 83 patients (77%) were continuing to receive crizotinib at the time of data cutoff, and the estimated 6-month progression-free survival rate was 72%, with no median for the study reached[29]. It is concluded that the inhibition of ALK in lung tumors with
the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients.

The overall prevalence of EML4-ALK translocation among patients with NSCLC is 3% to 5%, and EML4-ALK translocation is mainly observed among patients who are typically never or light smokers, adenocarcinoma, younger age of onset, and wild-type EGFR/K-Ras (e.g. mutually exclusive with EGFR and K-Ras mutations)\textsuperscript{28,30,31}. There is no strong evidence to suggest an ethnic difference of EML4-ALK translocation among patients with NSCLC. Because Eastern Asian patients with NSCLC have higher proportion of never-smokers and younger age of onset, it is likely that a higher prevalence of ALK\textsuperscript{+} may be observed among Eastern Asian patients than Caucasian patients.

Conclusions

Asian and Western patients with lung cancer have different characteristics for epidemiology (e.g. risk factors, demographics, and genetic susceptibility), clinical presentation, tumor biomarkers (e.g. EGFR and K-Ras mutation), response to target therapies, and prognosis. The exact mechanisms behind these differences are not clear. These ethnic differences should be taken into account when conducting global clinical trials that include different ethnic populations, where stratified analysis by race/ethnicity may need to be performed, and studies among Asian patients may need to be prioritized. In addition, Asia needs a guideline for the management of NSCLC because of differences in medical care, medical care insurance, ethnic variation, and drug approval lag within Asian countries compared with Western countries. It is suggested that Asian collaborative trials on treatment of NSCLC patients need to be started promptly to generate data from this important part of the world\textsuperscript{102}.

Acknowledgement

The authors thank Dr. Maurizio Voi from Pfizer Oncology for his critical reading and expert comments.

Received: 2011-03-17; revised: 2011-04-08; accepted: 2011-04-11.

References

[1] Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CA Cancer J Clin, 2011, 61(2):69–90.
[2] Ahn MJ, Lee J, Park YH, et al. Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non–small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era [J]. J Thorac Oncol, 2010, 5(8):1185–1196.
[3] Kawaguchi T, Matsumura A, Fuku S, et al. Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases [J]. J Thorac Oncol, 2010, 5(7):1001–1010.
[4] Zhang H, Cai B. The impact of tobacco on lung health in China [J]. Respiriology, 2003, 8(1):17–21.
[5] Molina JR, Yang P, Cassivi SD, et al. Non–small cell lung cancer: epidemiology, risk factors, treatment, and survivorship [J]. Mayo Clin Proc, 2008, 83(5):584–594.
[6] Lam WK. Lung cancer in Asian women—the environment and genes [J]. Respiriology, 2005, 10(4):406–417.
[7] Xu ZY, Brown L, Pan GW, et al. Lifestyle, environmental pollution and lung cancer in cities of Liaoning in Northeastern China [J]. Lung Cancer, 1996, 14 Suppl 1:S149–S160.
[8] Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25 [J]. Nat Genet, 2008, 40(5):616–622.
[9] McKay JD, Hung RJ, Gaborieau V, et al. Lung cancer susceptibility locus at 5p15.33 [J]. Nat Genet, 2008, 40(12):1404–1406.
[10] Wang Y, Broderick P, Webb E, et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk [J]. Nat Genet, 2008, 40(12):1407–1409.
[11] Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25 [J]. Nature, 2008, 452(7187):633–637.
[12] Hsiung CA, Lan Q, Hong YC, et al. The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia [J]. PLoS Genet, 2010, 6(8):e1001051.
[13] Ou SH, Zogas A, Zell JA. Asian ethnicity is a favorable prognostic factor for overall survival in non–small cell lung cancer (NSCLC) and is independent of smoking status [J]. J Thorac Oncol, 2009, 4(9):1083–1093.
[14] Ou SH, Zogas A, Zell JA. A comparison study of clinicopathologic characteristics of Southern California Asian American non–small cell lung cancer (NSCLC) patients by smoking status [J]. J Thorac Oncol, 2010, 5(2):158–168.
[15] Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non–small cell lung cancer (FLEX): an open-label randomised phase III trial [J]. Lancet, 2009, 373(9674):1525–1531.
[16] Gandara DR, Kawaguchi T, Crowley J, et al. Japanese-US common-arm analysis of pacitaxel plus carboplatin in advanced non–small-cell lung cancer: a model for assessing population-related pharmacogenomics [J]. J Clin Oncol, 2009, 27(21):3540–3546.
[17] Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and
meta-analysis of studies in advanced non–small-cell lung cancer and metastatic colorectal cancer [J]. Lancet Oncol, 2008,9(10):962–972.

[18] Mao C, Qiu LX, Liao RY, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non–small cell lung cancer: a meta-analysis of 22 studies [J]. Lung Cancer, 2010,69(3):272–278.

[19] Nomura M, Shigematsu H, Li L, et al. Polymorphisms, mutations, and amplification of the EGFR gene in non–small cell lung cancers [J]. PLoS Med, 2007,4(4):e125.

[20] Sekine I, Yamamoto N, Nishio K, et al. Emerging ethnic differences in lung cancer therapy [J]. Br J Cancer, 2008,99(11):1757–1762.

[21] Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma [J]. N Engl J Med, 2009,361(10):947–957.

[22] Yang CH, Fukuoka M, Mok TS, et al. Final overall survival results from a phase III, randomised, open-label, first-line study of gefitinib v carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (ipass) [A]. Italy, Milan, 35th European Society for Medical Oncology Congress, 2010.LBA2.

[23] Zhou CC, Wu YL, Chen G, et al. Efficacy results from the randomised phase III optimal (CTONG 0602) study comparing first-line erlotinib versus carboplatin plus gemcitabine, in Chinese advanced non–small-cell lung cancer patients with EGFR activating mutations [A]. Italy, Milan, 35th European Society for Medical Oncology Congress, 2010.LBA13.

[24] Jackman DM, Miller VA, Cioffredi LA, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non–small cell lung cancer patients: results of an online tumor registry of clinical trials [J]. Clin Cancer Res, 2009,15(16):5267–5273.

[25] Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma [J]. Clin Cancer Res, 2008,14(18):5731–5734.

[26] Wu CC, Hsu HY, Liu HP, et al. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications [J]. Cancer, 2008,113(11):3199–3208.

[27] Aviel-Ronen S, Blackhall FH, Shepherd FA, et al. K-ras mutations in non–small–cell lung carcinoma: a review [J]. Clin Lung Cancer, 2006,8(1):30–38.

[28] Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non–small-cell lung cancer [J]. Nature, 2007,448(7153):561–566.

[29] Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non–small–cell lung cancer [J]. N Engl J Med, 2010,363(18):1693–1703.

[30] Palmer RH, Venersson E, Grabbe C, et al. Anaplastic lymphoma kinase: signalling in development and disease [J]. Biochem J, 2009,420(3):345–361.

[31] Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer [J]. Clin Cancer Res, 2011.

[32] Saijo N, Fukuoka M, Thongprasert S, et al. Lung Cancer Working Group Report [J]. Jpn J Clin Oncol, 2010,40(Suppl 1):i7–i12.